126 related articles for article (PubMed ID: 15880133)
61. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
Ballova V; Ladicka M; Vranovsky A; Lakota J
Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
[TBL] [Abstract][Full Text] [Related]
62. Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease.
Tormey CA; Snyder EL; Cooper DL
Transfusion; 2008 Sep; 48(9):1930-3. PubMed ID: 18513256
[TBL] [Abstract][Full Text] [Related]
63. Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation.
Statkute L; Verda L; Oyama Y; Traynor A; Villa M; Shook T; Clifton R; Jovanovic B; Satkus J; Loh Y; Quigley K; Yaung K; Gonda E; Krosnjar N; Spahovic D; Burt RK
Bone Marrow Transplant; 2007 Mar; 39(6):317-29. PubMed ID: 17277794
[TBL] [Abstract][Full Text] [Related]
64. Local irradiation prior to stem cell harvest has no influence on CD34+ yield: a quantitative analysis.
Rinn JP; Schwella N; Wollmer E; Jaques G; Heinzel-Gutenbrunner M; Strassmann G; Gross MW; Movassaghi K; Neubauer A; Ritter M
Ann Hematol; 2006 Jan; 85(1):38-44. PubMed ID: 16012838
[TBL] [Abstract][Full Text] [Related]
65. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
66. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
Putkonen M; Rauhala A; Pelliniemi TT; Remes K
Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
[TBL] [Abstract][Full Text] [Related]
67. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
68. The number of CD34(+) cells in peripheral blood as a predictor of the CD34(+) yield in patients going to autologous stem cell transplantation.
Basquiera AL; Abichain P; Damonte JC; Ricchi B; Sturich AG; Palazzo ED; García JJ
J Clin Apher; 2006 Jul; 21(2):92-5. PubMed ID: 16106446
[TBL] [Abstract][Full Text] [Related]
69. Pegfilgrastim effectively mobilizes PBSC in a poor mobilizer multiple myeloma patient.
Malerba L; Mele A; Leopardi G; Stramigioli S; Politi P; Visani G
Eur J Haematol; 2006 May; 76(5):436-9. PubMed ID: 16480428
[TBL] [Abstract][Full Text] [Related]
70. The role of pegfilgrastim in mobilization of hematopoietic stem cells.
Kroschinsky F; Hölig K; Ehninger G
Transfus Apher Sci; 2008 Jun; 38(3):237-44. PubMed ID: 18490197
[TBL] [Abstract][Full Text] [Related]
71. An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia.
Viola A; Falco C; D'Elia R; D'Amico MR; Vicari L; Tambaro FP; Correale P; Laudati D; Palmieri S; Ferrara F
Eur J Haematol; 2007 Jan; 78(1):41-7. PubMed ID: 17042770
[TBL] [Abstract][Full Text] [Related]
72. The financial requirements and time commitments of caregivers for autologous stem cell transplant recipients.
Meehan KR; Fitzmaurice T; Root L; Kimtis E; Patchett L; Hill J
J Support Oncol; 2006 Apr; 4(4):187-90. PubMed ID: 16669462
[TBL] [Abstract][Full Text] [Related]
73. Costing of severe pneumonia in hospitalized infants and children aged 2-36 months, at a secondary and tertiary level hospital of a not-for-profit organization.
Madsen HO; Hanehøj M; Das AR; Moses PD; Rose W; Puliyel M; Konradsen F; John KR; Bose A
Trop Med Int Health; 2009 Oct; 14(10):1315-22. PubMed ID: 19719464
[TBL] [Abstract][Full Text] [Related]
74. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
75. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.
Majhail NS; Mothukuri JM; Brunstein CG; Weisdorf DJ
Biol Blood Marrow Transplant; 2009 May; 15(5):564-73. PubMed ID: 19361748
[TBL] [Abstract][Full Text] [Related]
76. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
[TBL] [Abstract][Full Text] [Related]
77. Vinorelbine plus intermediate dose cyclophosphamide is an effective and safe regimen for the mobilization of peripheral blood stem cells in patients with multiple myeloma.
Annunziata M; Celentano M; Pocali B; D'Amico MR; Palmieri S; Viola A; Copia C; Falco C; Del Vecchio L; Ferrara F
Ann Hematol; 2006 Jun; 85(6):394-9. PubMed ID: 16538502
[TBL] [Abstract][Full Text] [Related]
78. Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity.
Boiron JM; Dazey B; Cailliot C; Launay B; Attal M; Mazurier F; McNiece IK; Ivanovic Z; Caraux J; Marit G; Reiffers J
Transfusion; 2006 Nov; 46(11):1934-42. PubMed ID: 17076849
[TBL] [Abstract][Full Text] [Related]
79. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
80. [Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation].
Adam Z; Veselý K; Krejcí M; Pour L; Fakan F; Soumarová R; Neubauer J; Vanícek J; Cerný J; Kren L; Bolcák K; Smardová L; Hájek R; Mayer J
Vnitr Lek; 2009 Feb; 55(2):147-57. PubMed ID: 19348397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
